Department

Referred Work
ADAL

Preferred Sample Type

Adalimumab drug monitoring

Suitable Specimen Types

  • Serum
  • Li Hep
Minimum of 300uL of serum or plasma for both drug and anti drug antibody analysis

Specimen Transport

Sample sent via post to referral laboratory

Sample Processing in Laboratory

Sample separated and sent to referral laboratory

Sample Preparation

Sample collected into SST tube or Lithium Heparin tube

Turnaround Time

3 weeks

Sample Stability

Stable at 4C. If transport is going to be delayed by > 5 days, freeze at -20°C and send by first class post at a later date.

Adalimumab drug monitoring

General Information

Measurement of Adalimumab is a useful tool in the management of patients who fail to respond ( primary failure) or lose response ( secondary failure) to treatment. Monitoring drug levels allows for a personalised approach to drug optimisation by appropriate dose escalation/de-escalation or drug switching/withdrawal. Measured as part of Adalimumab profile which includes anti drug antibodies. Specific request form required for this assay download from: http://www.viapath.co.uk/sites/default/files/upload/News/Anti-TNF%20request%20formv6.pdf

Patient Preparation

No specific preparation required.

Notes

Adalimumab is a fully humanised monoclonal antibody which specifically targets tumour necrosis factor alpha (TNFα). Adalimumab is licensed for use in Gastroenterology (Crohn's diseases, ulcerative colitis), Rheumatology (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis) and Dermatology (severe plaque psoriasis). Adalimumab is only indicated in patients with severe disease which is refractory to conventional therapeutic approaches

Reference Range

Lower limit of the therapeutic range is yet to be established, however levels of greater than 5 µg/mL appear to be adequate.This information will be updated as we refine the therapeutic range. Test interpretation requires full clinical information: drug dosage/frequency, previous exposure to other biologics, time of sampling, duration of therapy and clinical assessment.

Specifications

  • EQA Scheme?: No
  • EQA Status: No EQA scheme currently available.

Link to Send Away Laboratory

http://www.viapath.co.uk/our-tests/adalimumab

Date Record Created

Thursday, 10 August 2017

Date last updated

Thursday, 21 May 2020

Review Date

Monday, 30 November -0001

Location of Laboratories

Patient Information

General Information

The laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital form part of the services provided by University Hospitals Birmingham and are UKAS (United Kingdom Accreditation Service) accredited to the ISO 15189:2012 standard. For a list of accredited tests and other information please visit the UKAS website using the following link: https://www.ukas.com/find-an-organisation/

  • Heartlands, Good Hope and Solihull Hospital pathology laboratories are a UKAS accredited medical laboratory No.8217
  • United Kingdom Health Security Agency laboratory is a UKAS accredited medical laboratory No.8213

Tests not appearing on the UKAS Schedule of Accreditation currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.

For further test information, please visit the test database: http://www.heftpathology.com/frontpage/test-database.html.

Protection of personal information - Laboratory Medicine comply with the Trust Data Protection policy and have procedures in place to allow the Directorate and its employees to comply with the Data Protection act  1998 and associated best practice and guidance.

For further information contact Louise Fallon, Quality Manager, 0121 424 1235

UKAS HEFT